Medicago Evaluates Plant-Derived COVID-19 Vaccine Candidate

Medicago and GlaxoSmithKline (GSK) have launched a global phase 3 trial evaluating Medicago’s plant-derived COVID-19 vaccine candidate when combined with GSK’s pandemic adjuvant.

The randomized, global phase 3 trial aims to enroll up to 30,000 participants, including healthy adults, elderly adults and adults with co-morbidities. Participants will receive two doses of the vaccine 21 days apart.

The FDA granted the plant-derived vaccine candidate in combination with the adjuvant Fast-Track designation in mid-February.

Medicago said it will also begin a feasibility study of an unspecified vaccine candidate aimed at targeting emerging COVID-19 variants.